ZielBio, Inc. Market Research Report

Background

ZielBio, Inc. is a clinical-stage biotechnology company dedicated to identifying novel disease targets and developing therapeutic interventions to improve patient outcomes. Founded in 2010 and headquartered in Charlottesville, Virginia, ZielBio leverages its proprietary drug discovery platform, ZielFind, to discover new treatments for cancer and other serious diseases.

Key Strategic Focus

ZielBio's strategic focus centers on:

Target Identification: Utilizing the ZielFind platform to identify high-value, druggable targets associated with various cancers.

Therapeutic Development: Developing therapies targeting cancer-specific plectin (CSP), a cell surface protein linked to poor prognosis and aggressive tumors.

Clinical Advancement: Progressing lead candidate ZB131 through clinical trials for multiple solid tumors, including cholangiocarcinoma, pancreatic, and ovarian cancers.

Financials and Funding

ZielBio has secured approximately $41 million in funding through various investment rounds. Notable investors include Morningside Group, 5Y Capital, Mass General Brigham Ventures, and Virginia Venture Partners. The most recent funding round, a later-stage venture capital investment of $15 million, occurred on September 27, 2022.

Pipeline Development

ZB131: ZielBio's lead asset, ZB131 (proposed international nonproprietary name Ibentatug), is a proprietary humanized monoclonal antibody targeting CSP. A Phase 1/2 clinical trial (NCT05074472) is underway to evaluate its safety, tolerability, and efficacy in patients with solid tumors, including cholangiocarcinoma, pancreatic, and ovarian cancers. The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ZB131 for the treatment of both cholangiocarcinoma and pancreatic cancer.

Technological Platform and Innovation

ZielFind Platform: This proprietary drug discovery platform combines functional, high-throughput screening with large-content data analytics to identify high-value targets. ZielFind has been instrumental in discovering CSP as a therapeutic target and developing ZB131.

Proprietary Technologies: ZB131 is a first-in-class humanized monoclonal antibody designed to bind specifically to CSP, which is expressed on the surface of cancer cells in many solid tumors. Preclinical studies have demonstrated ZB131's high specificity and strong anti-cancer activity.

Leadership Team

Alan S. Bash: Appointed Chief Executive Officer and Board Member in January 2023. Previously served as President and CEO of Checkmate Pharmaceuticals and held various leadership roles at Bristol Myers Squibb, including Senior Vice President for Immunology and Fibrosis.

Dr. Kimberly Kelly: Founder, President, Chief Operating Officer, and Board Member. Continues to lead the company's mission to bring innovative therapeutics to patients.

Dr. Maria Beconi: Chief Scientific Officer.

Gregg Beloff, JD: Chief Financial Officer.

Dieter Weinand: Executive Chairman.

Leadership Changes

In January 2023, Alan S. Bash was appointed as Chief Executive Officer and Board Member, succeeding Dr. Kimberly Kelly, who continues to serve as President, Chief Operating Officer, and Board Member.

Competitor Profile

Market Insights and Dynamics: The oncology therapeutics market is highly competitive, with numerous companies developing targeted therapies for various cancers. The market is characterized by rapid innovation, significant investment, and a strong focus on personalized medicine.

Competitor Analysis:

Monte Rosa Therapeutics: Focuses on targeted protein degradation to treat diseases caused by the loss or gain of protein function.

NexImmune: Develops immunotherapies based on its AIM nanoparticle technology to orchestrate a targeted immune response.

Aro Biotherapeutics: Specializes in developing Centyrins, a novel class of protein therapeutics for various diseases.

CytImmune Sciences: Pioneers the development of nanomedicines for the treatment of cancer.

CytomX Therapeutics: Develops Probody therapeutics designed to selectively activate in the tumor microenvironment.

These competitors are also engaged in developing innovative cancer therapies, contributing to a dynamic and rapidly evolving market landscape.

Strategic Collaborations and Partnerships

As of the latest available information, specific strategic collaborations or partnerships involving ZielBio have not been publicly disclosed.

Operational Insights

ZielBio's proprietary ZielFind platform and its focus on targeting CSP with ZB131 provide a distinct competitive advantage in the oncology therapeutics market. The company's ability to identify novel targets and develop corresponding therapies positions it uniquely among competitors.

Strategic Opportunities and Future Directions

ZielBio aims to advance ZB131 through clinical development, with plans to open Phase 2 expansion cohorts as monotherapy and in combination with standard-of-care therapeutics. The company continues to leverage its ZielFind platform to identify additional novel targets and expand its pipeline, reinforcing its commitment to addressing unmet needs in oncology.